EBI3通过调节Th17,PD-L1在肿瘤微环境中发挥免疫抑制作用的机制研究

基本信息
批准号:81402358
项目类别:青年科学基金项目
资助金额:23.00
负责人:勾红峰
学科分类:
依托单位:四川大学
批准年份:2014
结题年份:2017
起止时间:2015-01-01 - 2017-12-31
项目状态: 已结题
项目参与者:王玮,石华山,黄娟,聂雯,张鹏飞,张舰,文凤
关键词:
直肠肿瘤辅助性T细胞17C08_结肿瘤免疫逃逸EB病毒诱导基因3细胞程序性死亡配体1
结项摘要

Epstein-Barr virus-Induced gene 3(EBI3) protein is highly expressed in placental cells in pregnancy and has roles in maintenance of immune tolerance of the human maternal body toward the fetus. Morevoer,EBI3 has been found to highly expressed in several tumor tissue. However, the significance of EBI3 in carcinogenesis and tumor development was not clarified. Our pilot studies showed that the growth of tumor can be heavily suppressed in EBI3-/- mice. It is tempting to speculate that expression of EBI3 may promote tumor growth. EBI3, a secretory glycoprotein, has been shown to form IL-27,IL-35 and homodimer. It has been reported that EBI3 has strong immunosuppressive function in autoimmune disease and infection via inhibiting the function and differentiation of Th17 cells and adjusting the PD-L1 signal. In view of this, we speculate that EBI3 has strong immunosuppressive function in the tumor micro-environment by inhibiting Th17 cells and promoting the PD-L1 expression. We have confirmed Th17 changes in our pilot studies. Our proposed research aims at identifying the immunosuppressive function and how EBI3 can create strong immunosuppressive via Th17 and PD-L1 pathway. Specifically, we will validate our speculation in human colorectal tumor tissue. We strongly believe that our proposed research on identifying EBI3’s immunosuppressive function will establish the fundation to choose EBI3 as an anti-tumor immune therapeutic target.

EB病毒诱导蛋白(EBI3)在妊娠期间胎盘高表达,与免疫抑制密切相关。研究发现,EBI3表达于多种肿瘤,但在肿瘤发生发展中的作用尚不明确。我们前期在EBI3敲除小鼠中接种肿瘤,发现肿瘤生长较野生型明显延缓,反面提示EBI3表达可能促进肿瘤生长,但机制不清。EBI3作为一种分泌性糖蛋白,可以参与形成IL-27、IL-35或形成同源二聚体,在抑制Th17细胞功能和调节PD-L1信号中发挥对自身免疫和炎症的抑制作用。因此,我们推测:EBI3可能在肿瘤微环境中通过抑制Th17细胞,促进PD-L1表达发挥免疫抑制作用,进而促进免疫逃逸,促肿瘤生长。我们在前期研究中初步证实了Th17的变化,在本项目中,我们拟进一步证实EBI3的免疫抑制作用,阐明其免疫调节机制,并进一步在人肿瘤组织中进行验证。本项目的实施,不仅仅有助于理解EBI3介导肿瘤免疫逃逸的机制,还将为靶向抑制EBI3治疗肿瘤提供研究基础。

项目摘要

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

病毒性脑炎患儿脑电图、神经功能、免疫功能及相关因子水平检测与意义

病毒性脑炎患儿脑电图、神经功能、免疫功能及相关因子水平检测与意义

DOI:10.13210/j.cnki.jhmu.20190508.001
发表时间:2019
2

Enhanced piezoelectric properties of Mn-modified Bi5Ti3FeO15 for high-temperature applications

Enhanced piezoelectric properties of Mn-modified Bi5Ti3FeO15 for high-temperature applications

DOI:10.1111/jace.16978
发表时间:2020
3

奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展

奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展

DOI:
发表时间:2020
4

结直肠癌免疫治疗的多模态影像及分子影像评估

结直肠癌免疫治疗的多模态影像及分子影像评估

DOI:10.13609/j.cnki.1000-0313.2022.04.019
发表时间:2022
5

Research on parameter identification of Johnson–Cook constitutive model for TC17 titanium alloy cutting simulation

Research on parameter identification of Johnson–Cook constitutive model for TC17 titanium alloy cutting simulation

DOI:https://doi.org/10.1016/j.mtcomm.2022.103772
发表时间:2022

勾红峰的其他基金

批准号:81672397
批准年份:2016
资助金额:57.00
项目类别:面上项目

相似国自然基金

1

EBI3通过PD-1/PD-L1通路调控Treg 细胞表达介导DLBCL肿瘤免疫抑制机制的研究

批准号:81500173
批准年份:2015
负责人:黄娟
学科分类:H0810
资助金额:18.00
项目类别:青年科学基金项目
2

EZH2通过糖代谢调控肿瘤微环境中Treg细胞免疫调节功能的机制研究

批准号:81773048
批准年份:2017
负责人:赵恩德
学科分类:H1806
资助金额:65.00
项目类别:面上项目
3

结肠癌肿瘤微环境中pDCs通过PD-L1信号通路调控肿瘤进展和转移的作用及机制研究

批准号:81901591
批准年份:2019
负责人:吴静
学科分类:H1102
资助金额:21.00
项目类别:青年科学基金项目
4

CXCL13通过调控肿瘤免疫微环境诱导抗肿瘤免疫的机制研究

批准号:81402354
批准年份:2014
负责人:李丹
学科分类:H1806
资助金额:23.00
项目类别:青年科学基金项目